| Business Summary | | Photogen
Technologies,
Inc.
is
a
development-stage
biotechnology
company
focused
on
developing
minimally
invasive
products
for
the
treatment
and
diagnosis
of
cancer,
pre-cancerous
conditions
and
other
diseases.
The
Company
is
developing
compounds
that
react
with
energy
for
the
purpose
of
destroying
diseased
cells,
removing
tissue
or
identifying
and
diagnosing
disease.
Compounds
that
react
with
light
energy
are
called
"photoactive
agents,"
and
those
that
react
with
ionizing
radiation
(which
the
Company
generically
refers
to
as
X-rays)
are
called
"radiosensitizers."
The
Company
is
also
developing
agents
that
are
radiopaque
and
can
be
used
to
locate
lymphnodes
and
diagnosis
the
presence
or
absence
of
cancer
metastases.
The
Company
has
discovered
and
is
conducting
research
on
new
methods
and
apparatus
for
using
energy
from
lasers,
X-rays
or
other
sources
to
activate
energy-sensitive
compounds
within
tissue
to
produce
a
range
of
beneficial
therapeutic
and
diagnostic
outcomes. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Photogen
Technologies,
Inc.
is
an
emerging
development
stage
biotechnology
company
focused
on
developing
minimally
invasive
products
for
the
treatment
and
diagnosis
of
disease.
For
the
three
months
ended
3/31/01,
revenues
remained
flat
at
$0.
Net
loss
applicable
to
Common
increased
37%
to
$3.8
million.
Results
reflect
the
inclusion
of
a
$696
thousand
provision
for
future
lease
payments
and
decreased
investment
income. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
after
tax
earnings
were
-2,074. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Theodore Tannebaum, 67 Chairman | -- | Taffy Williams, Ph.D., 51 Pres,
CEO, Director | $331K | Brooks Boveroux, 57 CFO,
Sr. VP-Fin. | 247K | Timothy Scott, Ph.D., 42 COO | 117K | Reinhard Koenig, M.D., Ph.D., 40 Sr.
VP, Medical and Regulatory Affairs | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|